A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg. After taking the corresponding investigational product, participants are required to complete test procedures including QTc interval measurement , blood sampling, and vital sign monitoring. The entire test process lasts for 3 days. On the third day, after participants complete laboratory tests and are assessed by physicians as meeting the discharge criteria, they can be disc

Trial Details

NCT ID
NCT07162116
Phase
PHASE1
Sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • XY0206
  • Moxifloxacin (400 mg)
  • XY0206 Placebo
Locations (sample)
  • Zibo, Shandong, China|36.79056,118.06333

Key Eligibility Criteria

  • Participants voluntarily sign a written informed consent form.
  • Male or female; aged between 18 and 45 years old (inclusive).
  • Male participants weigh ≥ 50kg, female participants weigh ≥ 45kg, and their body mass index (BMI) is between 19.0 and 26.0 kg/m², inclusive.
  • Physical examination, laboratory tests, and all trial-related examinations (vital signs, electrocardiogram, chest X-ray, abdominal color Doppler ul…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →